Abstract 250P
Background
Treatment for cervical cancer can significantly affect a patient’s quality of life. The purpose of this research: to study the quality of life in patients with cervical cancer and to analyze the dependence of the quality of life indicators on radiation doses obtained when living in areas adjacent to the Semipalatinsk test site.
Methods
In this study, a survey was conducted of 20 patients (women aged 27 to 70 years, average age 52 years) who received chemoradiation therapy. The questionnaire to assess the quality of life, carried out after treatment, using the official versions of questionnaires EORTC QLQ-CX24. The QLQ-CX24 module includes functional and symptomatic scales. The assessment of individual radiation doses received while living in areas exposed to radioactive exposure was carried out in accordance with official guidelines.
Results
The results obtained for functional scales: overall quality of life 78.4 ± 15.2, body image 80.2 ± 15.3, sexual activity 20.4 ± 19.5, sexual satisfaction 52.4 ± 18.3, sexual/vaginal functioning 42.6 ± 19.8 points. For symptomatic scales: symptoms 15.6 ± 12.8, lymphadenoma 12.9 ± 15.4, peripheral neuropathy 23.9 ± 14.7, menopausal symptoms 33.3 ± 28.4, sexual anxiety 32.4 ± 22.5 points.
Individual radiation doses received by patients while living in radioactively contaminated territories range from 1.06 to 36.11 cSv. For the study group, the relationship between indicators of quality of life and individual radiation doses have not been established. It is impossible to unequivocally affirm the absence of this dependence due to the insufficient number and heterogeneity of the studied group in a number of parameters.
Conclusions
A sufficiently high scale value indicates the overall quality of life reflects a good level of functioning. The rather low levels of the scales of symptoms, lymphedema, peripheral neuropathy indicate the severity of this symptomatology during preventive exposure to PALS. For the study group, the relationship between indicators of quality of life and individual radiation doses have not been established.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session
194P - Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer
Presenter: Jun Zhou
Session: e-Poster Display Session
370P - Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: e-Poster Display Session
390P - A real-world clinical study of camrelizumab in the treatment of esophageal cancer
Presenter: Guoping Sun
Session: e-Poster Display Session
203P - Characterization of renal cell carcinoma (RCC) with VHL mutation
Presenter: Yanrui Zhang
Session: e-Poster Display Session
204P - Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: Final analysis of PARACHUTE study
Presenter: Ravindran Kanesvaran
Session: e-Poster Display Session
205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population
Presenter: Himani Manchala
Session: e-Poster Display Session
206P - Mutational signature in urothelial carcinoma with TP53 mutation
Presenter: Huan Liu
Session: e-Poster Display Session
207P - Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma
Presenter: wang Wang
Session: e-Poster Display Session
208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India
Presenter: Lekha Nair
Session: e-Poster Display Session